Cash, cash equivalents and marketable securities as of December 31, 2022 totaled $129.0 million
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OVID:
- Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
- Ovid Therapeutics confirms no deposits, accounts at Silicon Valley Bank
- Ovid Therapeutics announces publication of studies of OV350
- Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
- Ovid Therapeutics expands epilepsy development expertise